NR546 | NR546 Advanced Pharmacology
Psychopharmacology for the PMHNP Week 1 Exam
2 | Questions with Correct Answers and Expert
Explanation for Each Question | Chamberlain
1. Which of the following best describes the role of a partial agonist in the presence of
a full agonist?
A. It increases the overall efficacy of the full agonist.
B. It causes an irreversible bond that prevents any further signaling.
C. It acts as an antagonist by competing for receptor sites and lowering the net
response.
D. It shifts the dose-response curve to the left, increasing potency.
Correct Answer: C
Expert Explanation: A partial agonist has lower intrinsic activity than a full agonist.
When both are present, the partial agonist competes for the same receptor sites,
effectively reducing the maximum possible response. This resulting behavior is
characterized as antagonistic because it dampens the stronger signal produced by
the full agonist alone.
,2. Which cytochrome P450 enzyme is responsible for the metabolism of approximately
25% of all psychotropic medications, including many antidepressants and
antipsychotics?
A. CYP2D6
B. CYP3A4
C. CYP1A2
D. CYP2C19
Correct Answer: A
Expert Explanation: CYP2D6 is a major enzyme in the metabolism of many
psychiatric drugs, including SSRIs and many antipsychotics. It is highly polymorphic,
meaning patients may be poor, intermediate, extensive, or ultra-rapid metabolizers.
Understanding a patient’s CYP2D6 status is crucial for predicting drug levels and
potential side effects in clinical practice.
3. A patient is taking a drug that is a known CYP3A4 inhibitor. If they are prescribed a
second medication that is a substrate of CYP3A4, what is the most likely outcome?
A. The concentration of the second medication will increase, potentially causing
toxicity.
B. The concentration of the second medication will decrease.
,C. The first medication will become less effective.
D. There will be no change in plasma levels for either drug.
Correct Answer: A
Expert Explanation: Inhibitors slow down the metabolic activity of the specific
enzyme, which in this case is CYP3A4. When metabolism is inhibited, the substrate
drug is not broken down as quickly, leading to higher plasma levels. This increase in
concentration can lead to an increased risk of adverse effects or toxicity for the
substrate medication.
4. What is the primary mechanism of action for an inverse agonist?
A. It binds to the receptor and reduces constitutive activity below the baseline level.
B. It binds to the receptor and produces the same effect as an agonist.
C. It blocks the endogenous ligand from binding but has no effect on its own.
D. It binds to an allosteric site to enhance the agonist’s effect.
Correct Answer: A
Expert Explanation: Inverse agonists bind to the same receptor as agonists but
induce a pharmacological response opposite to that of the agonist. This is only
possible in systems that have constitutive activity, where receptors are active even
, without a ligand. By binding, the inverse agonist shuts down this baseline activity,
bringing it below the resting state.
5. Steady state is typically reached after how many half-lives of a medication?
A. 1 to 2 half-lives
B. 2 to 3 half-lives
C. 10 to 12 half-lives
D. 4 to 5 half-lives
Correct Answer: D
Expert Explanation: Steady state occurs when the rate of drug administration
equals the rate of drug elimination. It generally takes about four to five half-lives for
a drug to reach this point of equilibrium in the plasma. This concept is vital for
PMHNPs to remember when determining when to evaluate the full therapeutic
effect of a dose change.
6. The ‘master switch’ for the release of neurotransmitters is often considered to be:
A. Ligand-gated sodium channels
B. G-protein coupled receptors
C. Potassium leak channels
D. Voltage-sensitive calcium channels
Psychopharmacology for the PMHNP Week 1 Exam
2 | Questions with Correct Answers and Expert
Explanation for Each Question | Chamberlain
1. Which of the following best describes the role of a partial agonist in the presence of
a full agonist?
A. It increases the overall efficacy of the full agonist.
B. It causes an irreversible bond that prevents any further signaling.
C. It acts as an antagonist by competing for receptor sites and lowering the net
response.
D. It shifts the dose-response curve to the left, increasing potency.
Correct Answer: C
Expert Explanation: A partial agonist has lower intrinsic activity than a full agonist.
When both are present, the partial agonist competes for the same receptor sites,
effectively reducing the maximum possible response. This resulting behavior is
characterized as antagonistic because it dampens the stronger signal produced by
the full agonist alone.
,2. Which cytochrome P450 enzyme is responsible for the metabolism of approximately
25% of all psychotropic medications, including many antidepressants and
antipsychotics?
A. CYP2D6
B. CYP3A4
C. CYP1A2
D. CYP2C19
Correct Answer: A
Expert Explanation: CYP2D6 is a major enzyme in the metabolism of many
psychiatric drugs, including SSRIs and many antipsychotics. It is highly polymorphic,
meaning patients may be poor, intermediate, extensive, or ultra-rapid metabolizers.
Understanding a patient’s CYP2D6 status is crucial for predicting drug levels and
potential side effects in clinical practice.
3. A patient is taking a drug that is a known CYP3A4 inhibitor. If they are prescribed a
second medication that is a substrate of CYP3A4, what is the most likely outcome?
A. The concentration of the second medication will increase, potentially causing
toxicity.
B. The concentration of the second medication will decrease.
,C. The first medication will become less effective.
D. There will be no change in plasma levels for either drug.
Correct Answer: A
Expert Explanation: Inhibitors slow down the metabolic activity of the specific
enzyme, which in this case is CYP3A4. When metabolism is inhibited, the substrate
drug is not broken down as quickly, leading to higher plasma levels. This increase in
concentration can lead to an increased risk of adverse effects or toxicity for the
substrate medication.
4. What is the primary mechanism of action for an inverse agonist?
A. It binds to the receptor and reduces constitutive activity below the baseline level.
B. It binds to the receptor and produces the same effect as an agonist.
C. It blocks the endogenous ligand from binding but has no effect on its own.
D. It binds to an allosteric site to enhance the agonist’s effect.
Correct Answer: A
Expert Explanation: Inverse agonists bind to the same receptor as agonists but
induce a pharmacological response opposite to that of the agonist. This is only
possible in systems that have constitutive activity, where receptors are active even
, without a ligand. By binding, the inverse agonist shuts down this baseline activity,
bringing it below the resting state.
5. Steady state is typically reached after how many half-lives of a medication?
A. 1 to 2 half-lives
B. 2 to 3 half-lives
C. 10 to 12 half-lives
D. 4 to 5 half-lives
Correct Answer: D
Expert Explanation: Steady state occurs when the rate of drug administration
equals the rate of drug elimination. It generally takes about four to five half-lives for
a drug to reach this point of equilibrium in the plasma. This concept is vital for
PMHNPs to remember when determining when to evaluate the full therapeutic
effect of a dose change.
6. The ‘master switch’ for the release of neurotransmitters is often considered to be:
A. Ligand-gated sodium channels
B. G-protein coupled receptors
C. Potassium leak channels
D. Voltage-sensitive calcium channels
